BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Krastev Z, Jelev D, Antonov K, Petkova T, Atanasova E, Zheleva N, Tomov B, Boyanova Y, Mateva L. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. World J Gastroenterol 2016; 22(8): 2630-2635 [PMID: 26937151 DOI: 10.3748/wjg.v22.i8.2630]
URL: https://www.wjgnet.com/1007-9327/full/v22/i8/2630.htm
Number Citing Articles
1
Anna Szymanek-Pasternak, Karolina Rostkowska, Krzysztof Simon. Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantationBMJ Case Reports 2017; : bcr-2017-220152 doi: 10.1136/bcr-2017-220152
2
AntiviralsReactions Weekly 2016; 1597(1): 33 doi: 10.1007/s40278-016-16475-5
3
Vinicius Lins Ferreira, Leticia Paula Leonart, Ana Maria Della Rocca, Roberto Pontarolo. Analysis of Safety Outcomes in Chronic Hepatitis C Patients using Interferon-free Treatment: A Systematic Review of Case ReportsCurrent Drug Therapy 2019; 14(3): 210 doi: 10.2174/1574885514666190130162547
4
Carmen M. Preda, Corneliu P. Popescu, Cristian Baicus, Theodor A. Voiosu, Mircea Manuc, Corina Silvia Pop, Liana Gheorghe, Ioan Sporea, Anca Trifan, Marcel Tantau, Alina Tantau, Emanoil Ceausu, Doina Proca, Ileana Constantinescu, Simona M. Ruta, Mircea M. Diculescu, Alexandru Oproiu. Real‐world efficacy and safety of ombitasvir, paritaprevir/r+dasabuvir+ribavirin in genotype 1b patients with hepatitis C virus cirrhosisLiver International 2018; 38(4): 602 doi: 10.1111/liv.13550
5
C. Weil, D. Mehta, G. Koren, B. Pinsky, J. C. Samp, G. Chodick, V. Shalev. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real‐world data from a large healthcare providerJournal of Viral Hepatitis 2018; 25(2): 144 doi: 10.1111/jvh.12800